Thrombophilias and adverse pregnancy outcome – A confounded problem!

Summary

It was the objective of this study to analyse the influence of confounders, such as ethnicity, severity of illness and method of testing, in articles concerning the still moot relationship of thrombophilias to adverse pregnancy outcome (APO). Relevant casecontrol studies were identified using Medline and EMBASE databases between 1966 and 2006. Search terms were recurrent fetal loss, intrauterine fetal death, preeclampsia, HELLP-syndrome, eclampsia, fetal growth restriction, abruptio placentae, combined with maternal thrombophilias. Data was extracted from the articles per subgroup ofAPO regardless of confounder. These subgroups were tested if they fulfilled the heterogeneity testing criterion (I² > 35%) to weigh the influence of the confounder. Confounders were selected and examined with Mantel- Haenszel method. Increased thrombophilia prevalence was confirmed in most adverse pregnancy outcomes. Ethnicity, genetic testing only and severity of illness were confounders in the various forms of APO. Stronger relationships between factor V Leiden and severity of disease were found in 2^nd and 3^rd trimester than 1^st trimester recurrent fetal loss, in preeclampsia with: blood pressure ≥160/110 mmHg than ≥140/90 mmHg; proteinuria ≥5 grams per day than < 5 grams; onset before than after 28 weeks, in fetal growth restriction <3^rd percentile than <5^th, than <10^th, and in earlier occurrence of abruptio placentae than 3^rd trimester. In conclusion, reports on the prevalence of maternal thrombophilias and APO are influenced by various confounders, which are not always appropriately analysed. The differences we have identified reflect the differential impact of these confounders. These data emphasise the importance of more uniform research.

Keywords

Thrombophilia - pregnancy - confounders - illness severity

 

• References

• 1 Howard MA, Firkin BG, Healy DL. et al. Lupus anticoagulant in women with multiple spontaneous miscarriage. Am J Hematol 1987; 26: 175-178.
• 2 Christiansen OB. A fresh look at the causes and treatments of recurrent miscarriage, especially its immunological aspects. Hum Reprod Update 1996; 2: 271-293.
• 3 Reece EA, Gabrielli S, Cullen MT. et al. Recurrent adverse pregnancy outcome and antiphospholipid antibodies [see comments]. Am J Obstet Gynecol 1990; 163: 162-169.
• 4 Lockshin MD. Pregnancy loss in the antiphospholipid syndrome. Thromb Haemost 1999; 82: 641-648.
• 5 Balasch J, Creus M, Fabregues F. et al. Antiphospholipid antibodies and human reproductive failure. Hum Reprod 1996; 11: 2310-2315.
• 6 Rai RS, Regan L, Clifford K. et al. Antiphospholipid antibodies and beta 2-glycoprotein-I in 500 women with recurrent miscarriage: results of a comprehensive screening approach. Hum Reprod 1995; 10: 2001-2005.
• 7 Rasmussen A, Ravn P. High frequency of congenital thrombophilia in women with pathological pregnancies?. Acta Obstet Gynecol Scand 2004; 83: 808-817.
• 8 Kujovich JL. Thrombophilia and pregnancy complications. Am J Obstet Gynecol 2004; 191: 412-424.
• 9 Greer IA. Thrombophilia: implications for pregnancy outcome. Thromb Res 2003; 109: 73-81.
• 10 Kupferminc MJ. Thrombophilia and pregnancy. Reprod Biol Endocrinol 2003; 14: 111-133.
• 11 Howley HEA, Walker M, Rodger M. A systematic review of the association between factor V Leiden or prothrombin gene variant and intrauterine growth restriction. Am J Obstet Gynecol 2005; 192: 694-708.
• 12 Pabinger I, Vormittag R. Thrombophilia and pregnancy outcomes. J Thromb Haemost 2005; 3: 1603-1610.
• 13 Higgins JPT, Thompson SG, Deeks JJ. et al. Measuring inconsistency in meta-analyses. Br Med J 2003; 327: 557-560.
• 14 Mtiraoui A, Borgi L, Hizem S. et al. Prevalence of antiphospholipid antibodies, factor V G1691A (Leiden) and prothrombin G20210A mutations in early and late recurrent pregnancy loss. Eur J Obstet Gynecol Reprod Biol 2005; 119: 164-170.
• 15 Sottilotta G, Oriana V, Latella FL. et al. Genetic prothrombotic risk factors in women with unexplained pregnancy loss. Thomb Res 2006; 117: 681-684.
• 16 Jivraj S, Rai R, Underwood J. et al. Genetic thrombophillic mutations among couples with recurrent miscarriage. Hum Reprod 2006; 21: 1161-1165.
• 17 Younis JS, Brenner B, Ohel G. et al. Activated protein C resistance and factor V Leiden mutation can be associated with first-as well as second-trimester recurrent pregnancy loss. Am J Reprod Immunol 2000; 43: 31-35.
• 18 Wramsby ML, Sten-Linder M, Bremme K. Primary habitual abortions are associated with high frequency of factor V Leiden mutation. Fertil Steril 2000; 74: 987-991.
• 19 Weiner Z, Beck-Fruchter R, Weiss A. et al. Thrombophilia and stillbirth: a possible connection by intrauterine growth restriction. Br J Obstet Gynecol 2004; 111: 780-783.
• 20 Vossen CY, Preston FE, Conrad J. et al. Hereditary thrombohilias and fetal loss: a prospective follow-up study. J Thromb Haemost 2004; 2: 592-596.
• 21 Tal J, Schliamser LM, Leibovitz Z. et al. A possible role for activated protein C resistance in patients with first and second trimester pregnancy failure. Hum Reprod 1999; 14: 1624-1627.
• 22 Souza SS, Ferriani RA, Pontes AG. et al. Factor V leiden and factor II G20210A mutations in patients with recurrent abortion. Hum Reprod 1999; 14: 2448-2450.
• 23 Sarig G, Younis JS, Hoffman R. et al. Thrombophilia is common in women with idiopathic pregnancy loss and is associated with late pregnancy wastage. Fertil Steril 2002; 77: 342-347.
• 24 Ridker PM, Miletich JP, Buring JE. et al. Factor V Leiden mutation as a risk factor for recurrent pregnancy loss. Ann Intern Med 1998; 128: 1000-1003.
• 25 Rai R, Shlebak A, Cohen H. et al. Factor V Leiden and acquired activated protein C resistance among 1000 women with recurrent miscarriage. Hum Reprod 2001; 16: 961-965.
• 26 Pihusch R, Buchholz T, Lohse P. et al. Thrombophilic gene mutations and recurrent spontaneous abortion: prothrombin mutation increases the risk in the first trimester. Am J Reprod Immunol 2001; 46: 124-131.
• 27 Peaceman AM, Kalt S, Casele H. et al. Fetal death is not associated with an increased incidence of common thrombophilias. Am J Obstet Gynecol 2002; 187: S201.
• 28 Pauer HU, Neesen J, Hinney B. Factor V Leiden and its relevance in patients with recurrent abortions [letter]. Am J Obstet Gynecol 1998; 178: 629.
• 29 Nowak-Gottl U, Sonntag B, Junker R. et al. Evaluation of lipoprotein(a) and genetic prothrombotic risk factors in patients with recurrent foetal loss. Thromb Haemost 2000; 83: 350-351.
• 30 Murphy RP, Donoghue C, Nallen RJ. et al. Prospective evaluation of the risk conferred by factor V Leiden and thermolabile methylenetetrahydrofolate reductase polymorphisms in pregnancy. Arterioscler Thromb Vasc Biol 2000; 20: 266-270.
• 31 Meinardi JR, Middeldorp S, de Kam PJ. et al. Increased risk for fetal loss in carriers of the factor V Leiden mutation. Ann Intern Med 1999; 130: 736-739.
• 32 Martinelli I, Taioli E, Cetin I. et al. Mutations in coagulation factors in women with unexplained late fetal loss. N Engl J Med 2000; 343: 1015-1018.
• 33 Many A, Elad R, Yaron Y. et al. Third-trimester unexplained intrauterine fetal death is associated with inherited thrombophilia. Obstet Gynecol 2002; 99: 684-687.
• 34 Kutteh WH, Park VM, Deitcher SR. Hypercoagulable state mutation analysis in white patients with early first-trimester recurrent pregnancy loss [see comments]. Fertil Steril 1999; 71: 1048-1053.
• 35 Kupferminc MJ, Eldor A, Steinman N. et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy [see comments]. N Engl J Med 1999; 340: 9-13.
• 36 Jivraj S, Rai R, Choy S. et al. Genetic thrombophilic mutations and recurrent miscarriage: A prospective study. J Soc Gynecol Investig 2003; 10: 182A.
• 37 Hefler L, Jirecek S, Heim K. et al. Genetic polymorphisms associated with thrombophilia and vascular disease in women with unexplained late intrauterine fetal death: a multicenter study. J Soc Gynecol Investig 2004; 11: 42-44.
• 38 Gris JC, Ripart-Neveu S, Maugard C. et al. Prospective evaluation of the prevalence of haemostasis abnormalities in unexplained primary early recurrent miscarriages. The Nimes Obstetricians and Haematologists (NOHA) Study. Thromb Haemost 1997; 77: 1096-1103.
• 39 Grandone E, Margaglione M, Colaizzo D. et al. Factor V Leiden is associated with repeated and recurrent unexplained fetal losses. Thromb Haemost 1997; 77: 822-824.
• 40 Gonen R, Lavi N, Schliamser L. et al. Absence of association of inherited thrombophilia with unexplained third-trimester intrauterine fetal death. Am J Obstet Gynecol 2005; 192: 742-746.
• 41 Foka ZJ, Lambropoulos AF, Saravelos H. et al. Factor V leiden and prothrombin G20210A mutations, but not methylenetetrahydrofolate reductase C677T, are associated with recurrent miscarriages. Hum Reprod 2000; 15: 458-462.
• 42 Fatini C, Gensini F, Battaglini B. et al. Angiotensinconverting enzyme DD genotype, angiotensin type 1 receptor CC genotype, and hyperhomocysteinemia increase first-trimester fetal-loss susceptibility. Blood Coagul Fibrinolysis 2000; 11: 657-662.
• 43 Dizon-Townson DS, Kinney S, Branch DW. et al. The factor V Leiden mutation is not a common cause of recurrent miscarriage. J Reprod Immunol 1997; 34: 217-223.
• 44 Dilley C, Benito C, Hooper WC. et al. Mutations in the factor V, prothrombin and MTHFR genes are not risk factors for recurrent fetal loss. J Matern Fetal Neonatal Med. 2002: 176-182.
• 45 Carp H, Salomon O, Seidman D. et al. Prevalence of genetic markers for thrombophilia in recurrent pregnancy loss. Hum Reprod 2002; 17: 1633-1637.
• 46 Brenner B, Mandel H, Lanir N. et al. Activated protein C resistance can be associated with recurrent fetal loss. Br J Haematol 1997; 97: 551-554.
• 47 Balasch J, Reverter JC, Fabregues F. et al. First-trimester repeated abortion is not associated with activated protein C resistance. Hum Reprod 1997; 12: 1094-1097.
• 48 Alonso A, Soto I, Urgelles MF. et al. Acquired and inherited thrombophilia in women with unexplained fetal losses. Am J Obstet Gynecol 2002; 187: 1337-1342.
• 49 Agorastos T, Karavida A, Lambropoulos A. et al. Factor V Leiden and prothrombin G20210A mutations in pregnancies with adverse outcome. J Matern Fetal Neonatal Med 2002; 12: 267-273.
• 50 Brenner B, Sarig G, Weiner Z. et al. Thrombophilic polymorphisms are common in women with fetal loss without apparent cause. Thromb Haemost 1999; 82: 6-9.
• 51 Hohlagschwandtner M, Unfried G, Heinze G. et al. Combined thrombophilic polymorphisms in women with idiopathic recurrent miscarriage. Fertil Steril 2003; 79: 1141-1148.
• 52 Sullivan AE, Nelson L, Rice JA. et al. The factor V Leiden and G20210A mutations are rare in women with fetal death. Am J Reprod Immunol 2005; 54: 1-4.
• 53 Reznikoff-Etievan M, Cayol V, Carbonne B. et al. factor V Leiden and G20210A mutations are risk factors for very early recurrent miscarriage. Br J Obstet Gynecol 2001; 108: 1251-1254.
• 54 Finan R, Tamim HM, Ameem G. et al. Prevalence of factor V G1691A (factor V Leiden) and prothrombin G20210A gene mutations in a recurrent population. Am J Hematol 2002; 71: 300-305.
• 55 Grandone E, Margaglione M, Colaizzo D. et al. Factor V Leiden, C>T MTHFR polymorphism and genetic susceptibility to preeclampsia. Thromb Haemost 1997; 77: 1052-1054.
• 56 Ward K, Nelson L, Hastings S. et al. Factor V Leiden and the T235 variant of angiotensinogen as risk factors for preeclampsia: A prospective study. J Soc Gynecol Investig 1998; 5: 240.
• 57 Von Tempelhoff GF, Heilmann L, Spanuth E. et al. Incidence of the Factor V Leiden-mutation, coagulation inhibitor deficiency, and elevated antiphospholipid- antibodies in patients with preeclampsia or HELLP-Syndrome. Thromb Res 2000; 100: 363-365.
• 58 van Pampus M, Dekker GA, Wolf H. et al. High prevalence of hemostatic abnormalities in women with a history of severe preeclampsia. Am J Obstet Gynecol 1999; 180: 1146-1150.
• 59 O’Shaughnessy KM, Fu B, Ferraro F. et al. Factor V Leiden and thermolabile methylenetetrahydrofolate reductase gene variants in an East Anglian preeclampsia cohort. Hypertension 1999; 33: 1338-1341.
• 60 Rigo Jr. J, Nagy B, Fintor L. et al. Maternal and neonatal outcome of preeclamptic pregnancies: the potential roles of factor V Leiden mutation and 5,10 methylenetetrahydrofolate reductase. Hypertens Pregnancy 2000; 19: 163-172.
• 61 Prasmusinto D, Skrablin S, Fimmers R. et al. V. Ethnic differences in the association of factor V Leiden mutation and the C677T methylenetetrahydrofolate reductase gene polymorphism with preeclampsia. Eur J Obstet Gynecol Reprod Biol 2004; 112: 162-169.
• 62 Nap AW, Hamulyak K, van Oerle R. et al. Performance of a novel test to quantify activated protein C resistance in women with a history of pre-eclampsia. Eur J Obstet Gynecol Reprod Biol 2004; 113: 26-30.
• 63 Nagy B, Toth J, Rigo Jr. J. et al. Detection of factor V Leiden mutation in severe pre-eclamptic women. Clin Genet 1998; 53: 478-481.
• 64 Morrison E, Miedzybrodzka Z, Campbell D. et al. Prothrombotic genotypes are not associated with preeclamptic and gestational hypertension: Results from a large population-based study and systematic review. Thromb Haemost 2002; 87: 779-785.
• 65 Mello G, Paretti E, Marozio L. et al. Thrombophilia is significantly associated with severe preeclampsia. Hypertension. 2005: 1270-1274.
• 66 Livingston JC, Barton JR, Park V. et al. Maternal and Fetal Genetic Thrombophilias are Not Associated with Severe Preeclampsia. Am J Obstet Gynecol 2000; 182: s25.
• 67 Lindoff C. Preeclampsia is associated with a reduced response to activated protein C. Am J Obstet Gynecol 1997; 176: 457-460.
• 68 Kupferminc MJ, Fait G, Many A. et al. Severe preeclampsia and high frequency of genetic thrombophilic mutations. Obstet Gynecol 2000; 96: 45-49.
• 69 Kobashi G, Yamada H, Asano T. et al. The factor V Leiden mutation is not a common cause of pregnancyinduced hypertension in Japan. Semin Thromb Hemost 1999; 25: 487-489.
• 70 Kim YJ, Williamson RA, Murray JC. et al. Genetic susceptibility to preeclampsia: roles of cytosineto-thymine substitution at nucleotide 677 of the gene for methylenetetrahydrofolate reductase, 68-base pair insertion at nucleotide 844 of the gene for cystathionine beta-synthase, and factor V Leiden mutation. Am J Obstet Gynecol 2001; 184: 1211-1217.
• 71 Hira B, Pegoraro RJ, Rom L. et al. Absence of Factor V Leiden, thrombomodulin and prothrombin gene variants in Black South African women with preeclampsia and eclampsia. Br J Obstet Gynecol 2003; 110: 327-328.
• 72 Faisel F, Romppanen EL, Hiltunen M. et al. Susceptibility to pre-eclampsia in Finnish women is associated with R485K polymorphism in the factor V gene, not with Leiden mutation. Europ J Hum Genet 2004; 12: 187-191.
• 73 Dizon-Townson DS, Nelson LM, Easton K. et al. The factor V Leiden mutation may predispose women to severe preeclampsia. Am J Obstet Gynecol 1996; 175: 902-905.
• 74 De Groot C, Bloemenkamp KW, Duvekot EJ. et al. Preeclampsia and genetic risk factors for thrombosis: a case-control study. Am J Obstet Gynecol 1999; 181: 975-980.
• 75 Currie L, Peek M, Mansour J. et al. Prevalence of the Leiden mutation in infants from pregnancies affected by severe pre-eclampsia. Hypertens Pregnancy 2000; 19: 105.
• 76 Benedetto C, Marozio L, Salton L. et al. Factor V Leiden and factor II G20210A in preeclampsia and HELLP syndrome. Acta Obstet Gynecol Scand 2002; 81: 1095-1100.
• 77 Chikosi AB, Moodley J, Pegoraro RJ. et al. 5,10 methylenetetrahydrofolate reductase polymorphism in black South African women with pre-eclampsia. Br J Obstet Gynecol 1999; 106: 1219-20.
• 78 Ji I. Preeclampsia and risk factors of angiotensinogen, methylenetetrahydrofolate reductase (MTHFR) and factor V gene variants. Am J Obstet Gynecol 2003; 189: S113.
• 79 Kobashi G, Yamada H, Asano T. et al. Absence of association between a common mutation in the methylenetetrahydrofolate reductase gene and preeclampsia in Japanese women. Am J Med Genet 2000; 93: 122-125.
• 80 Merrill D, Green J, Williamson R. et al. Methylenetetrahydrofolate Reductase Gene Polymorphism and Preeclampsia. J Soc Gynecol Investig 1999; 6: 200A.
• 81 Pegoraro RJ, Chikosi A, Rom L. et al. Methylenetetrahydrofolate reductase gene polymorphisms in black South Africans and the association with preeclampsia. Acta Obstet Gynecol Scand 2004; 83: 449-454.
• 82 Powers RW, Minich LA, Lykins DL. et al. Methylenetetrahydrofolate reductase polymorphism, folate, and susceptibility to preeclampsia. J Soc Gynecol Investig 1999; 6: 74-79.
• 83 Prasmusinto D, Skrablin S, Hofstaetter C. et al. The methylenetetrahydrofolate reductase 677 C-->T polymorphism and preeclampsia in two populations. Obstet Gynecol 2002; 99: 1085-1092.
• 84 Raijmakers M, Zusterzeel P, Steegers EA. et al. Hyperhomocysteinemia: a risk factor for preeclampsia?. Eur J Obstet Gynecol Reprod Biol 2001; 95: 226-228.
• 85 Rajkovic A, Mahomed K, Rozen R. et al. Methylenetetrahydrofolate reductase 677 C --> T polymorphism, plasma folate, vitamin B(12) concentrations, and risk of preeclampsia among black African women from Zimbabwe. Mol Genet Metab 2000; 69: 33-39.
• 86 Sohda S, Arinami T, Hamada H. et al. Methylenetetrahydrofolate reductase polymorphism and preeclampsia. J Med Genet 1997; 34: 525-526.
• 87 Zusterzeel PL, Visser W, Blom HJ. et al. Methylenetetrahydrofolate reductase polymorphisms in preeclampsia and the HELLP syndrome. Hypertens Pregnancy 2000; 19: 299-307.
• 88 Powers RW, Evans RW, Majors AK. et al. Plasma homocysteine concentration is increased in preeclampsia and is associated with evidence of endothelial activation. Am J Obstet Gynecol 1998; 179: 1605-1611.
• 89 Verspyck E, Borg JY, le Cam-Duchez V. et al. Thrombophilia and fetal growth restriction. Eur J Obstet Gynecol Reprod Biol 2004; 113: 36-40.
• 90 McCowan L, Craigie S, Taylor R. et al. Inherited thrombophilias are not increased in idiopathic small for gestational age pregnancies. Am J Obstet Gynecol 2002; 187: S199.
• 91 Lee MJ, Oddoux C, Maturi J. et al. Factor V Leiden and prothrombin 20210 G-A mutations in association with severely growth restricted pregnancies. Am J Obstet Gynecol 2001; 184: S131.
• 92 Kupferminc MJ, Many A, Bar-Am A. et al. Mid-trimester severe intrauterine growth restriction is associated with a high prevalence of thrombophilia. Br J Obstet Gynecol 2002; 109: 1373-1376.
• 93 Kupferminc MJ, Peri H, Zwang E. et al. High prevalence of the prothrombin gene mutation in women with intruterine growth retardation, abruptio placentae and second trimester loss. Acta Obstet Gynecol Scand 2000; 79: 963-967.
• 94 Infante-Rivard C, Rivard GE, Yotov WV. et al. Absence of association of thrombophilia polymorphisms with intrauterine growth restriction. N Engl J Med 2002; 347: 19-25.
• 95 Franchi F, Cetin I, Tordos T. et al. Intrauterine growth restriction and genetic predisposition to thrombophilia to thrombophilia. Haematologica 2005; 89: 444-449.
• 96 De Vries JIP, Dekker GA, Huijgens PC. et al. Hyperhomocysteinaemia and protein S deficiency in complicated pregnancies. Br J Obstet Gynecol 1997; 104: 1248-1254.
• 97 Facchinetti F, Marozio L, Grandone E. et al. Thrombophilic mutations are a main risk factor for placental abruption. Haematologica 2003; 88: 785-788.
• 98 Prochazka M, Happach C, Marsal K. et al. Factor V Leiden in pregnancies complicated by placental abruption. Br J Obstet Gynecol 2003; 110: 462-466.
• 99 Wiener-Megnagi Z, Ben-Shlomo I, Goldberg Y. et al. Resistance to activated protein C and the leiden mutation: high prevalence in patients with abruptio placentae. Am J Obstet Gynecol 1998; 179: 1565-1567.
• 100 Martinelli P, Grandone E, Colaizzo D. et al. Familial thrombophilia and the occurrence of fetal growth restriction. Haematologica 2001; 86: 428-431.
• 101 Lachmeijer AM, Arngrimsson R, Bastiaans EJ. et al. Mutations in the gene for methylenetetrahydrofolate reductase, homocysteine levels, and vitamin status in women with a history of preeclampsia. Am J Obstet Gynecol 2001; 184: 394-402.
• 102 Abou-Nassar K, Kovacs MJ, Kahn SR. et al. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia. A randomized trial. Thromb Haemost 2007; 98: 163-171.
• 103 Rai R, Cohen H, Dave M. et al. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). Br Med J 1997; 314: 253-257.
• 104 Dolitzky M, Inbal A, Segal Y. et al. A randomized study of thromboprophylaxis in women with unexplained consecutive recurrent miscarriages. Fertil Steril 2006; 86: 362-366.